What makes Esperion Therapeutics Inc. (ESPR) Stock unique?
BofA Securities raised the price target for the Esperion Therapeutics Inc. (NASDAQ:ESPR) stock from “a Buy” to “a Neutral”. The rating was released on January 03, 2024, according to finviz. The stock was upgraded by BofA Securities, who disclosed in a research note on June 15, 2023, from Underperform to Buy and set the price […]
What is Esperion Therapeutics Inc.’s (ESPR) Stock Real Technical Picture?
BofA Securities raised the price target for the Esperion Therapeutics Inc. (NASDAQ:ESPR) stock from “a Buy” to “a Neutral”. The rating was released on January 03, 2024, according to finviz. The stock was upgraded by BofA Securities, who disclosed in a research note on June 15, 2023, from Underperform to Buy and set the price […]
Esperion Therapeutics Inc. (ESPR) Stock is Just Right Size-Neither Too Big Nor Too Small
BofA Securities raised the price target for the Esperion Therapeutics Inc. (NASDAQ:ESPR) stock from “a Buy” to “a Neutral”. The rating was released on January 03, 2024, according to finviz. The stock was upgraded by BofA Securities, who disclosed in a research note on June 15, 2023, from Underperform to Buy and set the price […]
Esperion Therapeutics Inc. (NASDAQ:ESPR) stock is trading 202.86 percent above its 52-week low
BofA Securities raised the price target for the Esperion Therapeutics Inc. (NASDAQ:ESPR) stock from “a Buy” to “a Neutral”. The rating was released on January 03, 2024, according to finviz. The stock was upgraded by BofA Securities, who disclosed in a research note on June 15, 2023, from Underperform to Buy and set the price […]
Esperion Therapeutics Inc. (NASDAQ:ESPR) Stock is trading at a margin of -15.00% From 20-Day SMA
BofA Securities raised the price target for the Esperion Therapeutics Inc. (NASDAQ:ESPR) stock from “a Buy” to “a Neutral”. The rating was released on January 03, 2024, according to finviz. The stock was upgraded by BofA Securities, who disclosed in a research note on June 15, 2023, from Underperform to Buy and set the price […]
Does A Technical Metric Suggest That Esperion Therapeutics Inc. (ESPR) Stock Is Ready To Rise?
BofA Securities raised the price target for the Esperion Therapeutics Inc. (NASDAQ:ESPR) stock from “a Buy” to “a Neutral”. The rating was released on January 03, 2024, according to finviz. The stock was upgraded by BofA Securities, who disclosed in a research note on June 15, 2023, from Underperform to Buy and set the price […]
Will Earnings Beat Estimates? Esperion Therapeutics Inc. (ESPR) Stock
BofA Securities raised the price target for the Esperion Therapeutics Inc. (NASDAQ:ESPR) stock from “a Buy” to “a Neutral”. The rating was released on January 03, 2024, according to finviz. The stock was upgraded by BofA Securities, who disclosed in a research note on June 15, 2023, from Underperform to Buy and set the price […]
Where are Investors’ Sentiments? Esperion Therapeutics Inc. (ESPR) Stock
BofA Securities raised the price target for the Esperion Therapeutics Inc. (NASDAQ:ESPR) stock from “a Buy” to “a Neutral”. The rating was released on January 03, 2024, according to finviz. The stock was upgraded by BofA Securities, who disclosed in a research note on June 15, 2023, from Underperform to Buy and set the price […]
The Underside Of Esperion Therapeutics Inc. (ESPR) Stock Is A Little Uncertain
BofA Securities raised the price target for the Esperion Therapeutics Inc. (NASDAQ:ESPR) stock from “a Buy” to “a Neutral”. The rating was released on January 03, 2024, according to finviz. Historical Earnings Surprises and Revenue Forecasts Profit is the most critical financial performance measure. Every investor in a business is looking forward to the earnings […]
Consensus Analyst Estimated Price Target of $8.54 for Esperion Therapeutics Inc. (NASDAQ:ESPR) Stock
BofA Securities raised the price target for the Esperion Therapeutics Inc. (NASDAQ:ESPR) stock from “a Buy” to “a Neutral”. The rating was released on January 03, 2024, according to finviz. Historical Earnings Surprises and Revenue Forecasts Profit is the most critical financial performance measure. Every investor in a business is looking forward to the earnings […]